 Shares of NGM Biopharmaceuticals Inc. NGM, -5.94 tumbled 67.4 in premarket trading on Monday after the company said its experimental treatment for an advanced form of macular degeneration did not meet the primary endpoint in a Phase 2 clinical trial. NGM said it plans to share additional information from the study at the Retina Societys annual meeting next month. 